JY
CRVS icon

Jeff Yass’s Corvus Pharmaceuticals CRVS Stock Holding History

Jeff Yass’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.1M Buy
274,500
+88,100
+47% +$1.22M ﹤0.01% 4996
2026
Q1 		$2.73M Sell
186,400
-73,800
-28% -$1.18M ﹤0.01% 5471
2025
Q4 		$2M Buy
260,200
+216,100
+490% +$1.7M ﹤0.01% 5660
2025
Q3 		$325K Buy
44,100
+16,700
+61% +$85.5K ﹤0.01% 9930
2025
Q2 		$110K Sell
27,400
-65,800
-71% -$239K ﹤0.01% 11740
2025
Q1 		$296K Sell
93,200
-31,100
-25% -$146K ﹤0.01% 10093
2024
Q4 		$665K Buy
124,300
+79,900
+180% +$596K ﹤0.01% 7966
2024
Q3 		$234K Buy
44,400
+30,000
+208% +$108K ﹤0.01% 10143
2024
Q2 		$26.2K Sell
14,400
-9,100
-39% -$17K ﹤0.01% 11601
2024
Q1 		$41.8K Sell
23,500
-17,900
-43% -$37.4K ﹤0.01% 11626
2023
Q4 		$72.9K Sell
41,400
-12,000
-22% -$17.5K ﹤0.01% 11530
2023
Q3 		$78K Sell
53,400
-21,500
-29% -$45.5K ﹤0.01% 11080
2023
Q2 		$172K Buy
+74,900
New +$156K ﹤0.01% 10431
2022
Q3 		– Sell
-17,200
Closed -$17K – 13286
2022
Q2 		$17K Sell
17,200
-9,300
-35% -$11.4K ﹤0.01% 12400
2022
Q1 		$43K Sell
26,500
-54,900
-67% -$101K ﹤0.01% 12368
2021
Q4 		$196K Sell
81,400
-129,800
-61% -$503K ﹤0.01% 11471
2021
Q3 		$1.02M Buy
211,200
+146,900
+228% +$435K ﹤0.01% 7507
2021
Q2 		$172K Sell
64,300
-24,500
-28% -$67.5K ﹤0.01% 11746
2021
Q1 		$274K Buy
88,800
+66,900
+305% +$242K ﹤0.01% 10787
2020
Q4 		$78K Buy
+21,900
New +$88.2K ﹤0.01% 10606

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Jeff Yass's CRVS Position: Q2 2026 in Review

Jeff Yass increased its Corvus Pharmaceuticals (CRVS) stake by 393% in Q2 2026, buying an estimated $2.11M and bringing the position to 190,641 shares worth $2.85M. The position accounts for ﹤0.01% of the portfolio, ranked #5739.

Jeff Yass first reported a position in CRVS in Q4 2019 and has held it in 21 quarters since. The position peaked at $5.43M in Q4 2024. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Jeff Yass held 190,641 shares of Corvus Pharmaceuticals worth $2.85M as of Q2 2026.
  • Jeff Yass bought 152,005 Corvus Pharmaceuticals shares in Q2 2026, an estimated $2.11M.
  • Corvus Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5739 holding.
  • Jeff Yass first reported a position in Corvus Pharmaceuticals in Q4 2019 and has held it in 21 quarters since.
  • Jeff Yass's Corvus Pharmaceuticals position peaked at $5.43M in Q4 2024.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.